Contact the Editorial Desk

Editorial correspondence

Long Island Peptides welcomes correspondence on the research record: a citation quoted inaccurately, a newly published trial on any of the four compounds covered here, or a regulatory update — such as a change in FDA or WADA status — that should be reflected on the references page. This is the most useful class of message this guide receives, and each one is read carefully.

The most actionable submissions specify the page in question, the exact passage being challenged, and a supporting reference — a DOI, PMID, or clinical-trial identifier wherever possible, so the proposed change can be checked against its source before anything is edited.

Editorial mailbox: editors@longislandpeptides.com

What this desk cannot do

So no message goes unanswered for the wrong reason, a few things fall outside what this guide can address. Long Island Peptides is a literature digest, not a clinical service or vendor, so it cannot:

• Advise on or recommend human use of CJC-1295, ipamorelin, tesamorelin, or the combination.
• Suggest a dose, schedule, or route of administration for any individual.
• Evaluate whether a cited finding applies to a specific person's situation.
• Sell, source, recommend, or help locate any compound from any supplier.
• Provide guidance on obtaining tesamorelin outside a licensed prescriber relationship.
• Advise athletes on anti-doping questions, given that all four compounds fall under WADA's peptide-hormone category.

Readers seeking medical guidance should consult a licensed clinician in their own jurisdiction. Responses to editorial correspondence are not guaranteed and may be delayed; the mailbox is monitored intermittently.